Floatz logo

Mogamulizumab

Peripheral T-Cell Lymphoma, Not Otherwise Specified

Kyowa Kirin Co., Ltd.monoclonal_antibodyPhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
73/ 100

Competitive context

128 Active assets in the Peripheral T-Cell Lymphoma, Not Otherwise Specified cohort.

Asset / SponsorPhaseRating
Pralatrexate
Peking University People's Hospital
Phase 4BBB
Prednisone
Tarapeutics Science Inc.
Phase 4BBB
Adriamycin
BeBetter Med Inc
Phase 4BBB
(+)-Vincristine
BeBetter Med Inc
Phase 4BBB
Cyclophosphamide
Tarapeutics Science Inc.
Phase 4BBB

View all 50 →

Same molecule, other indications

Mogamulizumab is also rated in:

primary cutaneous T-cell non-Hodgkin lymphomaActive
BB
Indicative · Phase 4
71 / 100
View asset →
adult T-cell leukemia/lymphomaActive
BB
Indicative · Phase 2
71 / 100
View asset →
mycosis fungoidesActive
BB
Indicative · Phase 2
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →